Nvidia Options Price in $280 Billion Earnings Swing 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Add as a preferred source on Google
UTRECHT, The Netherlands, April 19, 2018 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will report full year 2017 financial results on Thursday, April 26, 2018. Merus’ management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, April 26, 2018, to discuss the financial results and recent clinical and corporate developments.
To participate in the call, please dial (877) 260-1463 (U.S.) or (706) 643-5907 (international) and reference conference ID 6184636. A live webcast will be available on the Investors page of the Company's website, http://www.merus.nl. An archived webcast replay will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation. For additional information, please visit Merus’ website, www.merus.nl.
Contacts:
Investors:
Kimberly Minarovich
+1 646-368-8014
[email protected]
Media:
David Rosen
+1 212-600-1902
[email protected]
